Quantum-Si to showcase protein sequencing tech at genomics festival

BRANFORD, Conn. - Quantum-Si Incorporated (NASDAQ:QSI) announced it will be featured at the upcoming Festival of Genomics & Biodata Boston, where advances in protein sequencing technology for drug development will be highlighted.

Melissa Deck, Director of Platform at Liberate Bio, will present "Precision Proteomics: Advancing Drug Development with Next-Gen Protein Sequencing" on June 24, 2025. The presentation will demonstrate how Quantum-Si’s Platinum Pro instrument is being used in protein analysis. According to InvestingPro data, the company has demonstrated impressive revenue growth of 167.94% over the last twelve months, though analysts don’t expect profitability this year.

The session will cover single-molecule protein sequencing on a benchtop platform, methods for enhancing proteomics and therapeutic discovery, and applications of protein barcoding for multiplexed screening. Deck will also discuss the use of protein barcoding in nucleic acid-LNP therapeutic development. InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 19.24, indicating robust liquidity to support its technological developments.

Deck brings experience in CRISPR/Cas9 editing, gene therapy, and drug delivery innovation from previous leadership roles in biotech and pharmaceutical companies.

Quantum-Si develops technology for single-molecule protein analysis, offering a platform that enables real-time detection and direct access to protein insights. The company aims to simplify and accelerate protein analysis for researchers.

The announcement was made in a press release statement from the company, which develops proteomics technology focused on redefining protein analysis through single-molecule detection.

In other recent news, QuantumSi Inc. reported its Q1 2025 earnings, revealing a narrower-than-expected loss per share and a significant revenue increase compared to the previous year. The company reported an earnings per share (EPS) of -$0.11, which surpassed the forecast of -$0.17. Revenue reached $842,000, marking an 84% increase year-over-year, although it fell short of the anticipated $1.25 million. Despite the positive EPS surprise, the revenue miss might have contributed to the company’s stock decline in aftermarket trading. QuantumSi continues to invest in research and development, with plans to launch its Proteus platform in the second half of 2026. The company also maintains a strong cash position, with cash and equivalents totaling $232.6 million, providing a financial runway until the second half of 2027. QuantumSi’s management has expressed confidence in the long-term market opportunity in proteomics, emphasizing ongoing technological advancements and international expansion. The company has also highlighted uncertainties in NIH funding as a potential challenge impacting the U.S. academic market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.